心房分流治疗心力衰竭:随机对照RELIEVE-HF试验
RELIEVE-HF试验将508例症状性心衰患者随机分配至经导管心房分流植入或安慰剂手术,按LVEF≤40%和>40%分层。主要安全终点达标,但2年主要有效性终点无差异(win ratio 0.86)。预设探索性分析显示分流对LVEF降低患者有益,对LVEF保留患者有害。
要点
- 经导管心房分流植入安全,30天内无主要安全事件。
- 全人群2年主要有效性终点分流与安慰剂无差异。
- LVEF降低患者分流减少心血管事件,LVEF保留患者分流增加事件。
核心结论
- 经导管心房分流植入安全但未改善整体心衰患者结局。
- 预设探索性分析提示分流对LVEF降低患者有益,对LVEF保留患者有害。
研究设计与样本
- 按LVEF≤40%(206例)与>40%(302例)分层,中位年龄73.0岁,女性189例(37.2%)。
主要发现
- 主要安全终点:分流植入后无主要安全事件发生(97.5%置信上限1.5%;P<0.0001)。
- 2年主要有效性终点:分流组与安慰剂组无差异(win ratio 0.86 [95%CI 0.61-1.22];P=0.20)。
- LVEF降低患者:分流组年化心血管事件率49.0% vs 安慰剂组88.6%(相对风险0.55 [95%CI 0.42-0.73];P<0.0001)。
- LVEF保留患者:分流组年化心血管事件率60.2% vs 安慰剂组35.9%(相对风险1.68 [95%CI 1.29-2.19];P=0.0001;交互P<0.0001)。
- KCCQ总体 summary 评分变化在全体及亚组中均无组间差异。
临床怎么用
- 心房分流植入可用于LVEF降低的心衰患者以减少心血管事件,但应避免用于LVEF保留患者。
局限性
- LVEF亚组分析为预设探索性分析,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms and prognosis. METHODS: Patients with symptomatic HF with any left ventricular ejection fraction (LVEF) were randomized 1:1 to transcatheter shunt implantation versus a placebo procedure, stratified by reduced (≤40%) versus preserved (>40%) LVEF. The primary safety outcome was a composite of device-related or procedure-related major adverse cardiovascular or neurological events at 30 days compared with a prespecified performance goal of 11%. The primary effectiveness outcome was the hierarchical composite ranking of all-cause death, cardiac transplantation or left ventricular assist device implantation, HF hospitalization, outpatient worsening HF events, and change in quality of life from baseline measured by the Kansas City Cardiomyopathy Questionnaire overall summary score through maximum 2-year follow-up, assessed when the last enrolled patient reached 1-year follow-up, expressed as the win ratio. Prespecified hypothesis-generating analyses were performed in patients with reduced and preserved LVEF. RESULTS: Between October 24, 2018, and October 19, 2022, 508 patients were randomized at 94 sites in 11 countries to interatrial shunt treatment (n=250) or a placebo procedure (n=258). Median (25th and 75th percentiles) age was 73.0 years (66.0, 79.0), and 189 patients (37.2%) were women. Median LVEF was reduced (≤40%) in 206 patients (40.6%) and preserved (>40%) in 302 patients (59.4%). No primary safety events occurred after shunt implantation (upper 97.5% confidence limit, 1.5%; P<0.0001). There was no difference in the 2-year primary effectiveness outcome between the shunt and placebo procedure groups (win ratio, 0.86 [95% CI, 0.61-1.22]; P=0.20). However, patients with reduced LVEF had fewer adverse cardiovascular events with shunt treatment versus placebo (annualized rate 49.0% versus 88.6%; relative risk, 0.55 [95% CI, 0.42-0.73]; P<0.0001), whereas patients with preserved LVEF had more cardiovascular events with shunt treatment (annualized rate 60.2% versus 35.9%; relative risk, 1.68 [95% CI, 1.29-2.19]; P=0.0001; Pinteraction<0.0001). There were no between-group differences in change in Kansas City Cardiomyopathy Questionnaire overall summary score during follow-up in all patients or in those with reduced or preserved LVEF. CONCLUSIONS: Transcatheter interatrial shunt implantation was safe but did not improve outcomes in patients with HF. However, the results from a prespecified exploratory analysis in stratified randomized groups suggest that shunt implantation is beneficial in patients with reduced LVEF and harmful in patients with preserved LVEF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03499236.
引用
- Stone, Lindenfeld, Rodés-Cabau, et al. Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial. Circulation. 2024. PMID: 39308371. doi:10.1161/CIRCULATIONAHA.124.070870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。